Otsuka ICU Medical is investing $500m into expanding its US-based IV manufacturing provision to improve long-term supply resiliency.
The company, established by Otsuka Pharmaceutical Factory America, a subsidiary of Japan’s Otsuka, and ICU Medical in May 2025, plans to use the funds to construct a new 500,000-square-foot manufacturing facility and make significant upgrades to its existing 700,000-square-foot manufacturing site in Austin, Texas.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The site expansion represents the first major milestone since Otsuka’s US subsidiary and ICU Medical joined forces last year. Otsuka ICU Medical anticipates that the plans will advance its North American IV solutions manufacturing and innovation provision. The company has already been making efforts to obtain US Food and Drug Administration (FDA) approval for select overseas Otsuka manufacturing sites to supplement North American supply..
The overall US supply chain for IV-related products such as bags and fluids was severely impacted after damage to Baxter’s North Carolina-based facility during Hurricane Helene in September 2024.
The North American IV solutions market remains highly concentrated, with Otsuka ICU Medical highlighting that recent supply chain disruptions as in the case of Baxter brought the necessity for “resilient, geographically diversified” production into focus,
Baxter produces around 60% of the US supply of IV fluids. Following the damaged to its North Carolina facility due to Hurricane Helene, by November 2024, around 86% of healthcare providers were reporting IV-related product shortages.
Otsuka ICU Medical CEO, Yoshifumi Fujimoto, said: “This expansion reflects our commitment to long-term growth in a clinically essential market.
“By strengthening our US manufacturing footprint and introducing innovation, we are enhancing supply reliability for North American customers while positioning ourselves to better support future regulatory and legislative requirements.”
While not specifically referenced in Otsuka ICU Medical’s news release, the plans resonate with drives by pharmaceutical companies to expand their US-based manufacturing footprints, primarily in order to fulfil pharma-related incentives as outlined by the Trump administration. While medtech companies have not been as active as pharma companies in this regard due to less intense trade pressures, there is still an overall trend of life sciences onshoring in the US under the Trump administration.
For example, in June, Johnson and Johnson (J&J) invested $1bn into strengthening its vision manufacturing capabilities in Florida, part of the company’s broader plans to outlay $55bn into expanding its overall US manufacturing footprint through 2029.
